Member Info for Sisu

Wrong thread. But FWIW taken from the Avacta Learning application notes (http://learning.avactalifesciences.com/delta-app-note)

"Conclusion

Based on the results of the analysis above, this study showed conclusively that the Avacta AffiDX® SARS-CoV-2 Antigen Lateral Flow Test device is confirmed as being able to detect the SARS-CoV-2 Delta Variant of Concern in routine samples.

The SARS-CoV-2 Delta variant has a higher transmission rate and is prevalent in many countries. Rapid lateral flow COVID-19 tests are commonly used across the world for mass screening; hence it is important that these rapid antigen tests are accurately evaluated against the Delta variant. Very few SARS-CoV-2 rapid antigen tests that are currently available in the market have been clinically evaluated against the Delta variant and these studies are usually conducted based on in-silico laboratory approach instead of using real-life patient samples. In this study, the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test was independently validated against Delta Variant of Concern using routine, prospective clinical samples. The AffiDX® SARS-CoV-2 Antigen Lateral Flow Test uses novel Affimer® technology which is highly sensitive and specific for the detection of SARS-CoV-2 antigens in human anterior nasal swab samples.

This study provides further evidence that Affimer® technology can be successfully applied to rapid antigen diagnostic platforms. "

Weird take that one of the most promising cancer-fighting set of treatments/technologies in decades is b*llox but ok.

https://www.mpo-mag.com/contents/view_breaking-news/2021-10-11/deal-transforms-mologic-into-social-enterprise/

For those wanting a read

You can see these travelling back into Reykjavik (Iceland) - very fascinating pieces of kits & totally utilitarian in that they are heated solely hydroelectrically & geothermally. They grow all sorts, supply a lot of the country's fruit & veg (including bananas) and taste great.

Wonderful place, well worth a visit. I may even sell a couple dozen AVCT shares to fund another trip there in a couple of years time.

The demand certainly is exploding. The message is being hit home in many countries.

https://www.irishtimes.com/news/health/sales-of-covid-antigen-tests-expected-to-rise-in-run-up-to-christmas-1.4726211

https://www.irishtimes.com/news/health/antigen-tests-should-be-used-twice-weekly-by-people-doing-high-risk-activities-nphet-1.4726688

https://www.irishtimes.com/news/politics/antigen-tests-to-be-sold-at-subsidised-prices-amid-concerning-rise-in-covid-cases-1.4727431

Brilliant post Lilarch. The sheer depth of experience they have in just the therapeutic division alone is mind-blowing.

Also it's no coincidence Affimers are the magic bean to the highest efficacy LFT there is on the market for COVID. It will do the same for other LFT's targeting other usages.

Good weekend all. I certainly am going to as I have a rather good feeling about November :- )

They also upped their short on Dialight PLC by 1.04% to 1.42% of the company in early Jan. Dialight trade at >44% YTD. Photo-Me International at c.30% up since they upped their short this year also. 0.8% short on MADE.com end of September, +23% this month.

A real shame they possess such a lack of integrity in their workings by playing with a BioTech company that will save lives. Let's revisit in 3 months time and see how they sit.

"The partnership also provides LG Chem with rights to develop and commercialise other Affimer® and non-Affimer biotherapeutics combined with Affimer XT® half-life extension for a range of indications and Avacta could earn up to $55m in milestone payments for each of these new products. In addition, under the agreement Avacta will earn royalties on all future Affimer XT® product sales by LG Chem."

There are multiple more partnerships too. Moderna, Integumen, Astrea Bioseperations etc. Avacta owns the IP to the magic cog of all of these opportunities (which are therein funded by the company carrying them out). Avacta have a huge amount of shots at goal. Their first, of which has led to income, being the LFT - coincidentally is a market leader in its efficacy. Their 'next' which is to receive read out in a multiple of weeks/months, AVA6000, would make £50m cash look like pocket change if it is to be successful. The entire industry would turn eyes to it, if not the world.

Expand the trial in its participation (as outlined by the trial description rulings). Not expand as in grow the trial outside of that.

I think maybe it is no coincidence the AVA6000 principal investigator Professor Udai Banerji (deputy director of the Drug Development Unit at The Institute of Cancer Research) expanded the trial to his own hunting ground @ the Marsden after speaking of the excitement of the trial. We are >58 days post first dosing.

The risk v reward is fascinating within this stock, put simply the market may want the writing on the wall but that may be too late for us mere mortal investors.

Have a great weekend all.

AVA6000 P1 Clinical Trial Data is known to those making the decision to expand the clinical trial. If data were not known they would not be able to progress the trial and increase participants for safety concerns. Me & you aren't privy to the contents of the data - but we can rest easy knowing it isn't bad.

I really truly hope it is successful to some level, not just for any personal share interest reasons - but for the participants & their family. This trial has more effects than the possibility of a SP rerate - we should know more within weeks to a small number of months.

There aren't many other opportunities like this out there. The BoD know that, as do a handful of savvy investors.

A very small plethora of indubitable pieces of information on Avacta, currently. This is a small cutting of the amount of strings Avacta have. Not even touching on TMAC which is one of the most exciting potential developments, & one of which BoD have already expressed has received significant interest from Big Pharma companies.

- Re. AVA6000: Eficacy/safety improvements of 10%+ are regularly seen as as a success in Clinical P1 trials, understandably so. Within mice, dosing at 6x potency in comparison to standard Doxorubicin application, produced 18x as much Doxorubicin to the target tumour tissue in comparison to the heart. Data is already known as to the safety/eficacy of AVA6000 within man and the trial is expanding - every day that passes without news is fantastic news for Avacta. As far as I am lead to believe, it took four-five decades for Chemotheraphy to be approved from the first workings (of Paul Ehrlich). Avacta are looking to completely revolutionise this and potentially (hopefully) help contribute towards saving millions of lives. I hope there's not a soul out there wishing ill of this.

- >3.6BN valued LG Chem recently hit a pre-clinical development milestone with an Affimer bispecific product. They have been working with Affimers for over 3 years and have only stretched their costs in development utilising them for their therapeutic potential. This is not the only deal Avacta have in place, there are others. Moderna being one.

- Global Antibody market is worth ~$200bn. Affimers, an antibody mimetic, have been proved superior to antibodies in multiple ways. More versatile, cheaper, more specific (https://www.sciencedirect.com/science/article/pii/S1046592820301182) etc. This isn't to say Affimers will necessarily push antibodies into redundancy, but even if Affimers eat up a slice of the marketplace (i.e. as LG Chem are looking to do with Affimer XT, as a solitary example), this is a monumental piece of IP that Avacta own.

- The AffiDX is one of, if not the, most accurate lateral flow tests on the market. (https://bioservuk.com/product/avacta-affidx-sars-cov-2-antigen-lateral-flow-test/). Regardless of manufacturing, sales and otherwise - this will very likely open eyes in the industry. LFT's will sell & be used in their billions, even if no clear correlation between efficacy & sales/usage - I believe no company would turn down the ability to meet AVCT's superior LFT accuracy.

Remember each person (which may or may not be more than one username..) here will have an agenda of type including myself. Some will be to inform as dually as possible, some to try and create some form of upwards momentum for the share and some will be simply to cause fear. Some will want to create disillusion as to which side they sit, they will still have an agenda of a type.

Have a good day, week & month all.

I'll respond just once as I believe the entirety of the substance within my post hasn't been understood correctly.

Re. NDA, that is in regard to AVCT's LFT project & Medusa19 (not the individual in question). We do not know the stipulations of the NDA, but you are insinuating that an individual went into a meeting with AVCT and didn't like what they heard in regard to LFT is a hint at some LFT discussion going on; chances are the parachute of an NDA wouldn't allow such talks. Let alone market regulations around this.

I am VERY comfortable with AVCT as a company. Lastly, I'm not sure you've grasped the point of my comment - be careful with what you post. Have a good day. :-)

Sharestock, it may be wise to not hypothesise and post such a scenario in which is a) potentially defamatory to an individual and b) suggesting Avacta are speaking of news not in public domain (whilst under duress of a publicly confirmed NDA, also) to an individual shareholder.

I'm not one to trade but I've topped up my treasure chest with a couple of thousand more @ 120p to review end of Sept. Stars are aligning.

I think those working on Calibre's e-mails are going to be VERY busy for a few days/weeks/months/years! Regardless of SP & company-based incentives of getting these selling, it's a brilliant step for businesses/economies and health. Mathematically you really can't sit confidently after an Innova test, with AffiDX you really can. Oh and I don't need to tickle my brain.

Fantastic news, hope the PR company of both AVCT & Calibre pounce on this and get the news out - hotcakes and sell come to mind.

Innova will also be ruled out by the new Target Profile they have published. Very easy for us to be sceptical as we have seen it all with Innova (sadly), but they won't go >97% for a green light test (desired). Will take some serious forgery for that to happen. Again I won't say it's impossible.

https://www.gov.uk/government/news/government-sets-out-laws-to-validate-accuracy-of-private-covid-19-tests

A little birdy told me AVCT go at 98%... P.S. the sensitivity level they desire is 99.9%. :-)

Good news.

If AVCT are chosen, at any point, to be part of/the sovereign test then we set the bar.

"All private COVID-19 tests released onto UK market will need to meet a revised set of standards in line with those used by government"

Even if we aren't to be, we can easily meet whatever standard that is (given it isn't using pigs mucus as part of the testing protocol..)

"From 1 September 2021 all COVID-19 molecular and antigen tests available to purchase will require validation prior to sale on the UK market under new draft legislation set out today, bringing them in line with NHS Test and Trace test standards."

Pretty much rules Innova out (famous last words) as of Sept 1 - as what sort of legislation would have a validation methodology that would pass Innova and fail any other competent test.

Personally, I think we are in an absolutely fantastic position with all of this commotion going on - we sit with a world leading product... just let it unfold, it's going to be good.

Scardey, you'd have no problem finding the gentleman on Linkedin working for Medusa19 if he did. Obviously no need to share accordingly but will re-inforce any ideas for yourself, sure he will have. I have an idea of whom it may be. I have had Medusa totted in to play a heavy part for us, they haven't invested so heavily and stuck around for a giggle. Great work and appreciate the updates.

Not long now!

Is he there yet?